{"id":"dutasteride-tamsulosin","safety":{"commonSideEffects":[{"rate":"6-8","effect":"Erectile dysfunction"},{"rate":"3-5","effect":"Decreased libido"},{"rate":"8-10","effect":"Retrograde ejaculation"},{"rate":"2-4","effect":"Dizziness"},{"rate":"2-3","effect":"Headache"},{"rate":"1-2","effect":"Asthenia/fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dutasteride inhibits the enzyme 5-alpha reductase, which converts testosterone to dihydrotestosterone (DHT), thereby reducing prostate volume and improving urinary flow obstruction. Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, providing rapid symptomatic relief of lower urinary tract symptoms. Together, these agents address both the mechanical obstruction and dynamic component of benign prostatic hyperplasia.","oneSentence":"Dutasteride/Tamsulosin combines a 5-alpha reductase inhibitor and an alpha-1 adrenergic antagonist to reduce prostate size and relax urinary tract smooth muscle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:49.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia with lower urinary tract symptoms"}]},"trialDetails":[{"nctId":"NCT07444385","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects","status":"RECRUITING","sponsor":"Addpharma Inc.","startDate":"2026-02-26","conditions":"Benign Prostatic Hyperplasia","enrollment":44},{"nctId":"NCT01342367","phase":"NA","title":"Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2010-12-17","conditions":"Prostate Cancer","enrollment":74},{"nctId":"NCT06677177","phase":"NA","title":"The Efficacy of Nano-water in Combination With Tamsulosin- Dutasteride for Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"ALI KAMAL M. SAMI","startDate":"2016-02-16","conditions":"Lower Urinary Tract Symptoms","enrollment":210},{"nctId":"NCT06282731","phase":"EARLY_PHASE1","title":"The Changes of Urine Growth Factors Level","status":"COMPLETED","sponsor":"En Chu Kong Hospital","startDate":"2013-05-31","conditions":"Benign Prostatic Hyperplasia","enrollment":74},{"nctId":"NCT06264414","phase":"PHASE3","title":"Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia","status":"NOT_YET_RECRUITING","sponsor":"EMS","startDate":"2025-02","conditions":"Prostatic Hyperplasia, Benign, Erectile Dysfunction","enrollment":262},{"nctId":"NCT04831476","phase":"","title":"Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2021-09-01","conditions":"Benign Prostatic Hyperplasia","enrollment":1296},{"nctId":"NCT06001619","phase":"PHASE4","title":"Prostate Medication, Metabolism and Gut Microbiota","status":"RECRUITING","sponsor":"Turku University Hospital","startDate":"2022-12-01","conditions":"Prostatic Hyperplasia, Prostate Cancer","enrollment":100},{"nctId":"NCT02869971","phase":"PHASE3","title":"Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-08","conditions":"Benign Prostatic Hyperplasia","enrollment":90},{"nctId":"NCT04245566","phase":"PHASE3","title":"Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH","status":"UNKNOWN","sponsor":"Dominik Abt","startDate":"2021-09","conditions":"Benign Prostatic Hyperplasia, Pharmacotherapy, Prostatic Artery Embolization","enrollment":425},{"nctId":"NCT02058368","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-10","conditions":"Prostatic Hyperplasia","enrollment":607},{"nctId":"NCT00701779","phase":"PHASE4","title":"Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Siami, Paul F., M.D.","startDate":"2005-09","conditions":"Benign Prostatic Hyperplasia","enrollment":63},{"nctId":"NCT02058576","phase":"PHASE1","title":"Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-11","conditions":"Urologic Diseases","enrollment":77},{"nctId":"NCT02052713","phase":"PHASE1","title":"Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-19","conditions":"Urologic Diseases","enrollment":78},{"nctId":"NCT01777269","phase":"PHASE4","title":"Prospective Sexual Function Study for BPH Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-18","conditions":"Prostatic Hyperplasia","enrollment":489},{"nctId":"NCT01673490","phase":"PHASE4","title":"Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-06-29","conditions":"Prostatic Hyperplasia","enrollment":59},{"nctId":"NCT01294592","phase":"PHASE4","title":"Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-22","conditions":"Prostatic Hyperplasia","enrollment":742},{"nctId":"NCT02509104","phase":"PHASE1","title":"Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-30","conditions":"Prostatic Hyperplasia","enrollment":56},{"nctId":"NCT01471678","phase":"PHASE1","title":"Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-30","conditions":"Prostatic Hyperplasia","enrollment":27},{"nctId":"NCT01495026","phase":"PHASE1","title":"A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-06","conditions":"Prostatic Hyperplasia","enrollment":63},{"nctId":"NCT01957189","phase":"PHASE1","title":"This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-25","conditions":"Prostatic Hyperplasia","enrollment":24},{"nctId":"NCT02184585","phase":"PHASE1","title":"Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-10","conditions":"Prostatic Hyperplasia","enrollment":84},{"nctId":"NCT00537654","phase":"PHASE1","title":"A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-18","conditions":"Prostatic Hyperplasia","enrollment":81},{"nctId":"NCT00609596","phase":"PHASE1","title":"A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-26","conditions":"Prostatic Hyperplasia","enrollment":24},{"nctId":"NCT01323998","phase":"","title":"Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Prostatic Hyperplasia","enrollment":35032},{"nctId":"NCT01332435","phase":"","title":"Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Prostatic Hyperplasia","enrollment":6896},{"nctId":"NCT01657851","phase":"PHASE1","title":"Bioequivalence - Duodart Against Avodart & Omnic","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08-23","conditions":"Prostatic Hyperplasia","enrollment":35},{"nctId":"NCT01332487","phase":"","title":"Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Prostatic Hyperplasia","enrollment":4068},{"nctId":"NCT01254071","phase":"PHASE1","title":"A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-10","conditions":"Prostatic Hyperplasia","enrollment":86},{"nctId":"NCT01386983","phase":"","title":"Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Prostatic Hyperplasia","enrollment":332},{"nctId":"NCT01390870","phase":"","title":"Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Prostatic Hyperplasia","enrollment":400},{"nctId":"NCT01435954","phase":"","title":"Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Benign Prostatic Hyperplasia","enrollment":13551},{"nctId":"NCT00090103","phase":"PHASE3","title":"Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11","conditions":"Prostatic Hyperplasia","enrollment":4844},{"nctId":"NCT01830829","phase":"PHASE3","title":"JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)","status":"TERMINATED","sponsor":"Dr. J. Curtis Nickel","startDate":"2013-04","conditions":"Benign Prostatic Hyperplasia, Chronic Prostatitis","enrollment":1},{"nctId":"NCT00244309","phase":"PHASE3","title":"Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2005-11","conditions":"Prostate Cancer","enrollment":348}],"_emaApprovals":[],"_faersSignals":[{"count":92,"reaction":"DEATH"},{"count":87,"reaction":"DIZZINESS"},{"count":72,"reaction":"HYPOTENSION"},{"count":64,"reaction":"GAIT DISTURBANCE"},{"count":61,"reaction":"CONSTIPATION"},{"count":59,"reaction":"DIARRHOEA"},{"count":59,"reaction":"FATIGUE"},{"count":58,"reaction":"DRUG INEFFECTIVE"},{"count":57,"reaction":"FALL"},{"count":57,"reaction":"PYREXIA"}],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Duodart","combodart","Duodart® 0.5 mg / 0.4 mg"],"phase":"marketed","status":"active","brandName":"Dutasteride/Tamsulosin","genericName":"Dutasteride/Tamsulosin","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dutasteride/Tamsulosin combines a 5-alpha reductase inhibitor and an alpha-1 adrenergic antagonist to reduce prostate size and relax urinary tract smooth muscle. Used for Benign prostatic hyperplasia with lower urinary tract symptoms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}